Analyst Price Targets — CYTK
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| October 8, 2026 12:56 pm | Leonid Timashev | RBC Capital | $113.00 | $60.21 | TheFly | Cytokinetics price target raised to $113 from $112 at RBC Capital |
| August 13, 2026 10:28 am | — | Barclays | $110.00 | $75.64 | TheFly | Cytokinetics price target raised to $110 from $95 at Barclays |
| August 10, 2026 2:12 pm | Srikripa Devarakonda | Truist Financial | $112.00 | $76.45 | TheFly | Cytokinetics price target raised to $112 from $106 at Truist |
| August 7, 2026 1:27 pm | Serge Belanger | Needham | $112.00 | $76.32 | TheFly | Cytokinetics price target raised to $112 from $102 at Needham |
| August 7, 2026 12:12 pm | Leonid Timashev | RBC Capital | $112.00 | $77.59 | TheFly | Cytokinetics price target lowered to $112 from $117 at RBC Capital |
| July 7, 2026 11:30 am | Leonid Timashev | RBC Capital | $117.00 | $85.57 | TheFly | Cytokinetics price target lowered to $117 from $119 at RBC Capital |
| June 29, 2026 10:19 am | Ashwani Verma | UBS | $115.00 | $82.19 | TheFly | Cytokinetics upgraded to Buy from Neutral at UBS |
| June 24, 2026 11:01 am | — | Mizuho Securities | $118.00 | $80.01 | TheFly | Cytokinetics price target raised to $118 from $100 at Mizuho |
| June 17, 2026 11:34 am | Leonid Timashev | RBC Capital | $119.00 | $75.21 | StreetInsider | RBC Capital on Cytokinetics (CYTK): 'The stock is significantly undervalued despite today's move' |
| May 11, 2026 10:17 am | — | H.C. Wainwright | $140.00 | $76.91 | TheFly | Cytokinetics price target raised to $140 from $136 at H.C. Wainwright |
Latest News for CYTK
Cytokinetics (NASDAQ: CYTK - Get Free Report) and Zai Lab (NASDAQ: ZLAB - Get Free Report) are both mid-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, institutional ownership, risk, earnings and analyst recommendations. Risk and Volatility Cytokinetics has a beta of
SOUTH SAN FRANCISCO, Calif., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced four upcoming presentations, including two Late Breaking Clinical Research presentations and two oral presentations, at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2026 taking place in Phoenix, AZ from October 9 – 12, 2026.
Multi-center Prospective Study to Track Real-World Safety, Clinical Effectiveness, and Healthcare Resource Impact of MYQORZO in Routine Clinical Practice
Cytokinetics NASDAQ: CYTK executives outlined the company's commercial expansion plans, cardiovascular pipeline and business-development priorities during a Bernstein investor symposium, highlighting the launch of MYQORZO and clinical programs targeting several forms of heart failure.
Both face patent cliffs and pay generous dividends, but only one of them can tell you where its next wave of growth is coming from.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for CYTK.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.